Astria shareholders approve BioCryst acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- BuzzFeed cuts 35% of workforce in restructuring move
Astria Stockholders Vote to Approve Acquisition by BioCryst
January 21, 2026 4:00 PM ESTBOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astrias stockholders held on January 21, 2026, Astrias stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the Merger).
The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal... More
